{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:01:53Z","timestamp":1792008113280,"version":"4.4.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T00:00:00Z","timestamp":1532304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ymgme.2018.07.009","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T06:28:25Z","timestamp":1532327305000},"page":"153-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Non-clinical evaluation of JR-051 as a biosimilar to agalsidase beta for the treatment of Fabry disease"],"prefix":"10.1016","volume":"125","author":[{"given":"Hideto","family":"Morimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yae","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Yoden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Horie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Komurasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Mihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohtaro","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Hirato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2018.07.009_bb0005","series-title":"GeneReviews","article-title":"Fabry disease","author":"Mehta","year":"1993"},{"key":"10.1016\/j.ymgme.2018.07.009_bb0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2018.07.009_bb0015","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/jhg.2013.48","article-title":"Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study","volume":"58","author":"Inoue","year":"2013","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2018.07.009_bb0020","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2018.07.009_bb0025","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2018.07.009_bb0030","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2018.07.009_bb0035","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.0022-202X.2004.22425.x","article-title":"Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies","volume":"122","author":"Thurberg","year":"2004","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ymgme.2018.07.009_bb0040","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2018.07.009_bb0045","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2018.07.009_bb0050","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000168482","article-title":"Agalsidase alfa slows the decline in renal function in patients with Fabry disease","volume":"29","author":"Feriozzi","year":"2009","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.ymgme.2018.07.009_bb0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","article-title":"Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain","volume":"8","author":"Rombach","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.07.009_bb0060","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ymgme.2018.07.009_bb0065","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ymgme.2013.04.015","article-title":"A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease","volume":"109","author":"Hughes","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.07.009_bb0070","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13023-014-0169-6","article-title":"Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study","volume":"9","author":"Schiffmann","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.07.009_bb0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ymgmr.2015.02.002","article-title":"Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry Outcome Survey analysis","volume":"3","author":"Beck","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2018.07.009_bb0080","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","article-title":"Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10\u202fyears' treatment","volume":"10","author":"Kampmann","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.07.009_bb0085","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2147\/DDDT.S102761","article-title":"An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are na\u00efve to enzyme replacement therapy","volume":"10","author":"Goker-Alpan","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymgme.2018.07.009_bb0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ymgmr.2017.10.008","article-title":"Long-term outcomes with agalsidase alfa enzyme replacement therapy: analysis using deconstructed composite events","volume":"14","author":"Beck","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2018.07.009_bb0095","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40360-017-0152-7","article-title":"Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-na\u00efve Fabry disease patients","volume":"18","author":"Tsuboi","year":"2017","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.ymgme.2018.07.009_bb0100","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","article-title":"Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study","volume":"55","author":"Arends","year":"2018","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2018.07.009_bb0105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bcp.12931","article-title":"Japanese regulation of biosimilar products: past experience and current challenges","volume":"82","author":"Arato","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ymgme.2018.07.009_bb0110","author":"ICH"},{"key":"10.1016\/j.ymgme.2018.07.009_bb0115","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease","volume":"13","author":"Lee","year":"2013","journal-title":"Glycobiology"},{"key":"10.1016\/j.ymgme.2018.07.009_bb0120","doi-asserted-by":"crossref","first-page":"6967","DOI":"10.1073\/pnas.78.11.6967","article-title":"Morphologic study of the internalization of a lysosomal enzyme by the mannose 6-phosphate receptor in cultured Chinese hamster ovary cells","volume":"78","author":"Willingham","year":"1981","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2018.07.009_bb0125","doi-asserted-by":"crossref","first-page":"47205","DOI":"10.1074\/jbc.M208534200","article-title":"Localization of the carbohydrate recognition sites of the insulin-like growth factor II\/mannose 6-phosphate receptor to domains 3 and 9 of the extracytoplasmic region","volume":"277","author":"Hancock","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2018.07.009_bb0130","author":"Genzyme Briefing Document"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218304086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218304086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T00:20:42Z","timestamp":1538698842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719218304086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":26,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1096719218304086"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.07.009","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-clinical evaluation of JR-051 as a biosimilar to agalsidase beta for the treatment of Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}